Norway· NO-ID_5F62B320-FA08-4E3C-8EF8-ABCDDB32F680
Spevigo
A spesolimab product containing spesolimab, registered in Norway by LEO PHARMA A/S (Danmark). The same ATC class is registered in 14 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Spesolimab is registered in 14 of 19 countries.
Countries holding a registration under ATC L04AC22 (spesolimab), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 9 of them publish a price we can compare per daily dose
Spesolimab · ATC L04AC22
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FEST (Norway)- Active substance
- Spesolimab
- Manufacturer
- LEO PHARMA A/S (Danmark)
- Country
- Norway (NO)
- ATC code
- L04AC22
- ATC class
- Spesolimab
- Defined daily dose
- 0.9 g, P
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- no_merkevare_idID_5F62B320-FA08-4E3C-8EF8-ABCDDB32F680
- no_varenummer1579222 x 7.5NOK 247317.5
- gtin4048846022769
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Spesolimab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumSpevigo 450 mgLeo Pharma
- CzechiaSPEVIGOLEO Pharma A/S, Ballerup
- FinlandSpevigoLeo Pharma A/S
- IrelandSpevigo 450 mg concentrate for solution for infusionLEO Pharma A/S
- IcelandSpevigoLEO Pharma A/S*
- PolandSpevigoBoehringer Ingelheim International GmbH
- SwedenSpevigo 450 mg Koncentrat till infusionsvätska, lösningLEO Pharma A/S
- United StatesSPEVIGOBoehringer Ingelheim Pharmaceuticals, Inc.
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Spevigo
- Liechtenstein · Spevigo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/15a9cd17-2732-4af7-a334-908937bc4134 GET /v1/drugs/15a9cd17-2732-4af7-a334-908937bc4134?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Konsentrat til infusjonsvæske, oppløsning",
"source": "fest",
"status": "A",
"atc_name": "Spesolimab",
"merkevare_id": "ID_5F62B320-FA08-4E3C-8EF8-ABCDDB32F680",
"name_form_strength": "Spevigo kons til inf oppl 450 mg",
"prescription_group": "C"
}See everything about spesolimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.